Table 1.
Cohort demographics and disease characteristics
| Demographics | Psoriasis (N = 207) | Controls (N = 76) | p-value |
|---|---|---|---|
| Mean ± SEM or N (%) | Mean ± SEM or N (%) | ||
| Age (years) | 47.8 ± 1.0 | 48.8 ± 2.0 | 0.651 |
| Gender (male) | 114 (55.1 %) | 40 (52.6 %) | 0.715 |
| Race (not Caucasian) | 24 (11.6 %) | 9 (11.8 %) | 0.954 |
| Characteristics of interest | |||
| BMI (kg/m2) | 30.9 ± 0.5 | 28.9 ± 0.1 | 0.025 |
| Current smoker | 78 (37.7 %) | 14 (18.4 %) | 0.002 |
| Dyslipidemia | 110 (53.1 %) | 28 (36.8 %) | 0.022 |
| Systolic blood pressure | 131 ± 1.3 | 123 ± 2.2 | 0.002 |
| Fasting blood glucose (mg/dL) | 94.7 ± 1.7 | 91.6 ± 1.4 | 0.184 |
| HDL (mg/dL) | 51.1 ± 1.0 | 55.9 ± 1.5 | 0.009 |
| Hypertension | 95 (45.9 %) | 19 (25.0 %) | 0.001 |
| hsCRP | 5.6 ± 0.7 | 3.3 ± 1.0 | 0.003 |
| LDL (mg/dL) | 121.2 ± 2.5 | 110.4 ± 3.9 | 0.027 |
| Statin therapy | 44 (21.3 %) | 16 (21.1 %) | 0.97 |
| Total cholesterol (mg/dL) | 197.4 ± 3.0 | 188.9 ± 4.7 | 0.128 |
| Triglyceride (mg/dL) | 125.9 ± 5.4 | 115.2 ± 11.3 | 0.392 |
| Waist circumference (in) | 40.2 ± 0.5 | 38.4 ± 0.6 | 0.028 |
| Coronary artery calcium (CAC) | 159 ± 32 | 130 ± 52 | 0.649 |
| 10 year Framingham risk score | 5.8 ± 0.4 | 4.8 ± 0.8 | 0.235 |
| Psoriasis specific | |||
| BSA | 14.3 ± 1.3 | N/A | ND |
| PASI | 10 ± 0.7 | N/A | ND |
| PGA | 2.2 ± 0.1 | N/A | ND |
| Psoriasis arthritis | 51 (24.6 %) | N/A | ND |
| Psoriasis duration (years) | 19.4 ± 1.0 | N/A | ND |
| Psoriasis treatment(s) | |||
| Biologics | 49 (23.7 %) | N/A | ND |
| Cyclosporine | 5 (2.4 %) | N/A | ND |
| Methotrexate | 13 (6.3 %) | N/A | ND |
| Narrow band UVB | 13 (6.3 %) | N/A | ND |
| Oral retinoids | 7 (3.4 %) | N/A | ND |
| Topicals | 96 (46.4 %) | N/A | ND |